Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rak wątroby (hepatocelularny) na podstawie badania biopsji lub obrazowania medycznego
- •Rak, który nie da się całkowicie usunąć chirurgicznie, rozprzestrzenił się lub jest zaawansowany
- •Wcześniejsze leczenie atezolizumabem z bevacizumabem, które przestało działać (pacjenci w drugiej linii leczenia)
- •Ogólny stan zdrowia pozwalający na leczenie (ocena 0-1 w skali ECOG)
- •Wątroba w stosunkowo dobrym stanie (klasa Child Pugh A)
- •Co najmniej jeden widoczny guz, który nie był dotychczas leczony lokalnie
- •Gotowość do regularnych wizyt w szpitalu i pobierania próbek krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (16)
Mayo Clinic in Arizona
Scottsdale, United States
Mayo Clinic in Florida
Jacksonville, United States
Cleveland Clinic Weston Florida
Weston, United States
University of Chicago Comprehensive Cancer Center
Chicago, United States
Carle Cancer Center NCI Community Oncology Research Program
Urbana, United States
University Medical Center New Orleans
New Orleans, United States
Michigan Cancer Research Consortium NCORP
Ann Arbor, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
Mayo Clinic in Rochester
Rochester, United States
Roswell Park Cancer Institute
Buffalo, United States
Duke University Medical Center
Durham, United States
University Hospitals Cleveland Medical Center
Cleveland, United States
Allegheny General Hospital
Pittsburgh, United States
Rapid City Regional Hospital
Rapid City, United States
Froedtert and the Medical College of Wisconsin LAPS
Milwaukee, United States
Medical College of Wisconsin
Milwaukee, United States
Trial contact
Laurie Mihalik
Tanios S. Bekaii-Saab
PRINCIPAL_INVESTIGATOR
Amanda Spratt
Chih-Yi Liao
PRINCIPAL_INVESTIGATOR
Hannah Parks
Suparna Mantha
PRINCIPAL_INVESTIGATOR
Jyostna Fuloira
Jyotsna Fuloria
PRINCIPAL_INVESTIGATOR
Christina Velfing
Elie G. Dib
PRINCIPAL_INVESTIGATOR
Cindy Rekowski
Oxana V. Crysler
PRINCIPAL_INVESTIGATOR
Katie L Wittenberger
Lori Martinez
Nguyen Tran
PRINCIPAL_INVESTIGATOR
Deeponpaul Singh
Renuka V. Iyer
PRINCIPAL_INVESTIGATOR
Jackie Hahn-Efrati
Dulabh K. Monga
PRINCIPAL_INVESTIGATOR
Angie Dunbar
Abdel-Ghani Azzouqa
PRINCIPAL_INVESTIGATOR
Dawn Carini
Marc Casati
Aditya Shreenivas
PRINCIPAL_INVESTIGATOR
Stacey L. Zindars
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.